Equities Analysts Offer Predictions for MDGL Q3 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at HC Wainwright issued their Q3 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a report released on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will post earnings per share of ($1.14) for the quarter. HC Wainwright has a “Buy” rating and a $500.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($6.79) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($4.25) EPS, FY2028 earnings at $34.48 EPS and FY2029 earnings at $69.75 EPS.

Several other equities analysts also recently commented on the stock. UBS Group restated a “buy” rating and issued a $523.00 price target (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. JMP Securities boosted their price target on shares of Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 20th. Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. TD Cowen boosted their target price on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Finally, Canaccord Genuity Group boosted their target price on shares of Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $471.13.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $448.73 on Monday. The company has a fifty day simple moving average of $356.02 and a two-hundred day simple moving average of $324.53. The company has a market cap of $9.96 billion, a price-to-earnings ratio of -34.92 and a beta of -1.02. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. Madrigal Pharmaceuticals has a 52 week low of $200.63 and a 52 week high of $457.16.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($3.48) by $1.58. The business had revenue of $212.80 million during the quarter, compared to the consensus estimate of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The company’s quarterly revenue was up 1357.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($7.10) earnings per share.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its stake in Madrigal Pharmaceuticals by 7.9% in the first quarter. Rhumbline Advisers now owns 26,364 shares of the biopharmaceutical company’s stock valued at $8,733,000 after acquiring an additional 1,924 shares in the last quarter. GAMMA Investing LLC boosted its stake in Madrigal Pharmaceuticals by 131.4% in the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 67 shares in the last quarter. XTX Topco Ltd acquired a new position in Madrigal Pharmaceuticals in the first quarter valued at $392,000. Park Avenue Securities LLC acquired a new position in Madrigal Pharmaceuticals in the first quarter valued at $217,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Madrigal Pharmaceuticals by 0.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 151,251 shares of the biopharmaceutical company’s stock valued at $50,099,000 after acquiring an additional 505 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Activity

In other news, Director Bros. Advisors Lp Baker bought 68,618 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was purchased at an average price of $364.04 per share, for a total transaction of $24,979,696.72. Following the completion of the purchase, the director owned 1,859,091 shares in the company, valued at approximately $676,783,487.64. This trade represents a 3.83% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William John Sibold sold 7,616 shares of the company’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $400.18, for a total transaction of $3,047,770.88. Following the completion of the transaction, the chief executive officer owned 109,753 shares of the company’s stock, valued at $43,920,955.54. This represents a 6.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 165,683 shares of company stock valued at $61,921,142 and have sold 309,019 shares valued at $112,705,072. 21.50% of the stock is currently owned by company insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.